Akebia raises $41 million series C

Anemia company Akebia Therapeutics Inc. (Cincinnati, Ohio) raised $41 million in a series C round co-led by new investors Satter Investment Management and Novo A/S. Existing investors Novartis Venture Fund; Kearny Venture Partners; Venture Investors; Athenian Venture Partners; Triathlon Medical Ventures; AgeChem Venture Fund; and Sigvion Capital also participated. Seaview Securities advised Akebia. Satter Investment's Muneer Satter joined Akebia's board as co-chairman. Novo A/S's Jack Nielsen and Kim Dueholm and Novartis Venture Fund's Giovanni Ferrara also joined Akebia's board. ...